Inventor
Dong Yu
Inventor
Westboro, MA, US
Overview
Patents· 66 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes25%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C07HSugars20%
C12NMicroorganisms or enzymes17%
Y02ATechnologies for adaptation to climate change4%
C07KPeptides3%
Y02PClimate change mitigation technologies in the production or processing of goods3%
A01NPreservation of bodies of humans or animals or plants or parts thereof1%
A61NElectrotherapy1%
C07DHeterocyclic compounds1%
PatentTitleYear
10,066,230Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response201810,041,076Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response201810,000,761DNA molecule used for recombinant 20189,453,228'Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response'20169,260,719'Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response'20169,243,050'Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8'20169,206,430'Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response'20158,946,175'Stabilized immunomodulatory oligonucleotides'20158,759,310'Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8'20148,716,253'Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes'20148,476,416'Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes'20138,431,544'Compositions for inhibiting gene expression and uses thereof'20138,426,375'Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response'20138,420,615'Immunostimulatory oligonucleotide multimers'20138,399,423'Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response'20138,383,598'Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response'20138,377,898'Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response'20138,361,986'Synthetic agonists of TLR9'20138,357,665'Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response'20138,202,850'Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends'20128,153,777'Modulation of toll-like receptor 5 expression by antisense oligonucleotides'20128,153,608'Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides'20128,153,605'Modulation of toll-like receptor 3 expression by antisense oligonucleotides'20128,106,173'Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8'20128,030,462'Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes'20118,008,267'Stabilized immunomodulatory oligonucleotides'20117,960,362'Synthetic agonists of TLR9'20117,932,367'Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes'20117,884,197'Synthetic agonists of TLR9'20117,875,594'Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents'20117,863,250'Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides'20117,851,454'Short immunomodulatory oligonucleotides'20107,851,453'Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides'20107,833,538'Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes'20107,824,696'Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes'20107,812,000'Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends'20107,790,168'Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes'20107,776,834'Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides'20107,749,975'Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends'20107,632,822'Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides'20097,595,305'Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides'20097,569,554'Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents'20097,566,702'Immunostimulatory oligonucleotide multimers'20097,517,862'Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends'20097,498,426'Immunostimulatory oligonucleotide multimers'20097,498,425'Immunostimulatory oligonucleotide multimers'20097,470,674'Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides'20087,427,405'Immunostimulatory oligonucleotide multimers'20087,407,944'Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends'20087,405,285'Immunostimulatory oligonucleotide multimers'20087,354,907'Short immunomodulatory oligonucleotides'20087,276,489'Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends'20077,262,286'Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes'20076,531,589'Base protecting groups and synthons for oligonucleotide synthesis'20036,509,459'Base protecting groups and rapid process for oligonucleotide synthesis'20036,140,482'Primary phosphoramidate internucleoside linkages and oligonucleotides containing the same'20006,117,993'Synthons for oligonucleotide synthesis'20006,063,778'Cephalosporin derivatives and processes for the preparation thereof'20005,962,674'Synthesis of oligonucleotides containing alkylphosphonate internucleoside linkages'19995,955,599'Process for making oligonucleotides containing o- and s- methylphosphotriester internucleoside linkages'19995,847,104'Method of tritium labeling oligonucleotide'19985,808,042'Detritylation of DMT-oligonucleotides using cationic ion-exchange resin'19985,750,674'Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced'19985,668,262'Method of tritium labeling oligonucleotides'19975,631,361'Method of synthesizing radioisotopically labeled oligonucleotides by direct solid-phase 5\' phosphitylation'19975,614,622'5-pentenoyl moiety as a nucleoside-amino protecting group, 4-pentenoyl-protected nucleotide synthons, and related oligonucleotide syntheses'1997Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1997–2003Patents assigned to HYBRIDON INC (11)· patent assignee history
1997–2003Based in Shrewsbury, MA, US· patent location history
1998–2000Based in Somerville, MA, US· patent location history
2007–2018Patents assigned to IDERA PHARMACEUTICALS INC (50)· patent assignee history
2007–2018Based in Westboro, MA, US· patent location history
2012–2015Patents assigned to AGRAWAL SUDHIR (17)· patent assignee history
2012–2015Patents assigned to YU DONG (17)· patent assignee history
2012–2015Patents assigned to BHAGAT LAKSHMI (12)· patent assignee history
2015Based in Cambridge, MA, US· patent location history
2018Based in Suzhou, CN· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| IDERA PHARMACEUTICALS INC | 50 | 2007–2018 |
| AGRAWAL SUDHIR | 17 | 2012–2015 |
| YU DONGself | 17 | 2012–2015 |
| BHAGAT LAKSHMI | 12 | 2012–2015 |
| HYBRIDON INC | 11 | 1997–2003 |
Locations
| Location | Patents | Span |
|---|---|---|
| Westboro, Massachusetts, US | 51 | 2007–2018 |
| Shrewsbury, Massachusetts, US | 9 | 1997–2003 |
| Somerville, Massachusetts, US | 2 | 1998–2000 |
| Suzhou, CN | 1 | 2018 |
| Cambridge, Massachusetts, US | 1 | 2015 |